Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AXSM

Axsome Therapeutics (AXSM)

Axsome Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AXSM
DateTimeSourceHeadlineSymbolCompany
12/06/202406:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
12/06/202406:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AXSMAxsome Therapeutics Inc
05/06/202421:38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AXSMAxsome Therapeutics Inc
05/06/202421:35GlobeNewswire Inc.Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem LaboratoriesNASDAQ:AXSMAxsome Therapeutics Inc
04/06/202421:00GlobeNewswire Inc.Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness MonthNASDAQ:AXSMAxsome Therapeutics Inc
03/06/202421:00GlobeNewswire Inc.Axsome Therapeutics Supports Alzheimer’s & Brain Awareness MonthNASDAQ:AXSMAxsome Therapeutics Inc
30/05/202421:00GlobeNewswire Inc.Axsome Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:AXSMAxsome Therapeutics Inc
30/05/202410:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
30/05/202410:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
30/05/202406:24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
30/05/202406:23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
29/05/202421:00GlobeNewswire Inc.Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024NASDAQ:AXSMAxsome Therapeutics Inc
29/05/202406:28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
28/05/202421:00GlobeNewswire Inc.Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) MeetingNASDAQ:AXSMAxsome Therapeutics Inc
08/05/202421:00GlobeNewswire Inc.Axsome Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:AXSMAxsome Therapeutics Inc
07/05/202407:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AXSMAxsome Therapeutics Inc
06/05/202422:09IH Market NewsIndex Futures Point to Strong Monday Opening, Building on Last Week’s Gains; Oil Prices RiseNASDAQ:AXSMAxsome Therapeutics Inc
06/05/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AXSMAxsome Therapeutics Inc
06/05/202421:00GlobeNewswire Inc.Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AXSMAxsome Therapeutics Inc
01/05/202421:00GlobeNewswire Inc.Axsome Therapeutics Recognizes May as Mental Health Awareness MonthNASDAQ:AXSMAxsome Therapeutics Inc
15/04/202421:00GlobeNewswire Inc.Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual MeetingNASDAQ:AXSMAxsome Therapeutics Inc
10/04/202421:00GlobeNewswire Inc.Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6NASDAQ:AXSMAxsome Therapeutics Inc
01/04/202422:00GlobeNewswire Inc.Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating DisorderNASDAQ:AXSMAxsome Therapeutics Inc
25/03/202422:00GlobeNewswire Inc.Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 PatientsNASDAQ:AXSMAxsome Therapeutics Inc
25/03/202421:30GlobeNewswire Inc.Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in NarcolepsyNASDAQ:AXSMAxsome Therapeutics Inc
19/03/202422:00GlobeNewswire Inc.Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive DisorderNASDAQ:AXSMAxsome Therapeutics Inc
05/03/202423:00GlobeNewswire Inc.Axsome Therapeutics to Present at the Leerink Partners Global Biopharma ConferenceNASDAQ:AXSMAxsome Therapeutics Inc
01/03/202410:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
01/03/202410:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
01/03/202409:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AXSM